/u/H2AK119ub's posts in /r/biotech

Year:

Only show posts with narrations

Bristol Myers telegraphs layoffs in New Jersey, trimming 117 jobs in staggered wave of cuts

94 upvotes

Mark as read: Add to a list

Jim Wilson, prominent gene therapy researcher, to depart UPenn

75 upvotes

Mark as read: Add to a list

FDA signs off on Adaptimmune's Tecelra as the first engineered cell therapy for a solid tumor

61 upvotes

Mark as read: Add to a list

Venture capital veteran venBio raises $528M for life sciences investment

42 upvotes

Mark as read: Add to a list

BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific

40 upvotes

Mark as read: Add to a list

Last year, Biogen’s CEO said no risky deals. Now, he’s ready to be bold

34 upvotes

Mark as read: Add to a list

BioNTech posts €808M loss as company continues to come to grips with seasonal COVID vaccine market

26 upvotes

Mark as read: Add to a list

Eli Lilly, after tirzepatide's late-stage cardio win, plots regulatory filings this year

16 upvotes

Mark as read: Add to a list

Introducing Fierce Biotech's 2024 Fierce 15

14 upvotes

Mark as read: Add to a list

Moderna takes axe to '24 sales guidance, sending shares lower

12 upvotes

Mark as read: Add to a list

Title	Upvotes	Mark as read	Favorited	Rating	Add to a list
Bristol Myers telegraphs layoffs in New Jersey, trimming 117 jobs in staggered wave of cuts	94
Jim Wilson, prominent gene therapy researcher, to depart UPenn	75
FDA signs off on Adaptimmune's Tecelra as the first engineered cell therapy for a solid tumor	61
Venture capital veteran venBio raises $528M for life sciences investment	42
BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific	40
Last year, Biogen’s CEO said no risky deals. Now, he’s ready to be bold	34
BioNTech posts €808M loss as company continues to come to grips with seasonal COVID vaccine market	26
Eli Lilly, after tirzepatide's late-stage cardio win, plots regulatory filings this year	16
Introducing Fierce Biotech's 2024 Fierce 15	14
Moderna takes axe to '24 sales guidance, sending shares lower	12